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Brazil introduced rotavirus vaccination in March 2006. 
We studied 133 rotavirus-positive fecal samples collected 
from February 2005 through December 2007. Genotype 
G2P[4] was found in 1.4% of samples in 2005, in 44% in 
2006, and in 96% in 2007. Rotavirus detection rate de-
creased from 38% in 2005 to 24% in 2007 (p = 0.012).
G
roup A rotaviruses (RV-A) are the major etiologic 
agents of acute diarrhea in infants, causing ≈611,000 
deaths each year (1). The recently developed attenuated 
G1P[8] vaccine, Rotarix (GlaxoSmithKline, Rixensart, 
Belgium), was included in the Brazilian Expanded Immu-
nization Program and, after March 2006, became available 
to the whole birth cohort. Rio de Janeiro is the second larg-
est Brazilian city; vaccine coverage was 43.3% in 2006 and 
74.4% in 2007. Although Rotarix was highly efﬁ  cacious 
for preventing severe RV gastroenteritis in phase III tri-
als carried out in Latin America and Europe, it appears to 
be less effective in preventing diarrhea caused by G2P[4] 
RV-A strains, which do not share either the VP7 or the VP4 
surface antigen with the vaccine strain (2). 
Initial studies carried out in northeastern Brazil after 
RV-A vaccine introduction demonstrated the predomi-
nance of RV-A G2P[4] in vaccinated populations (3–5). 
Also, the apparent extinction of non-G2 rotavirus strains 
from circulation was associated with a signiﬁ  cant reduction 
in the frequency of RV-A detection in children with gas-
troenteritis (5). This ﬁ  nding suggests that G2P[4] strains 
could be, to some extent, replacing P[8] genotypes in the 
postvaccination period.  
Sentinel RV-A surveillance, performed in selected 
pediatric settings as part of the strategies of immunization 
programs in Latin America, has been recommended to bet-
ter assess RV-A effects and strain characterization. In this 
context, studies carried out in Brazil demonstrated that the 
emergence of G9P[8] RV-A in Rio de Janeiro in the late 
1990s was accompanied by the disappearance of common 
genotypes like G2P[4] and G3P[8] and the continuous de-
tection of RV-A genotype G1P[8] (6–10). RV-A G5, an 
atypical genotype prevalent in the early 1990s, has not 
been detected in Rio de Janeiro since 1997 (6–10). In this 
study, we estimated the distribution of RV-A genotypes in 
hospitalized children in Rio de Janeiro before and after the 
monovalent RV-A vaccine was introduced into the national 
immunization schedule. 
The Study
From February 2005 through December 2007, fecal 
samples were collected from 464 hospitalized children 
from birth to 5 years of age who exhibited gastroenteritis 
and dehydration and required intravenous ﬂ  uid replace-
ment. The study was conducted in Salles Netto Municipal 
Hospital, a pediatric unit in Rio de Janeiro.
Most children studied (390 [84%]) were not eligible 
for full vaccination; they either were born before January 
1, 2006, or were <4 months of age. Nevertheless, 39 (8.4%) 
had been vaccinated with 2 doses of Rotarix, and 35 (7.5%) 
did not receive the vaccine.
Samples were collected after written consent was giv-
en by the parents. This study was approved by the Oswaldo 
Cruz Foundation Ethical Research Committee (protocol 
no. 311/06).
Polyacrylamide gel electrophoresis and a combined 
enzyme immunoassay for RV-A strains and adenoviruses 
were used to detect RV-A. Most samples were G- and P-
typed through seminested reverse transcription–PCR, as 
described (11). Seventeen RV-A–positive samples were P-
typed through partial genome sequencing. This method was 
also used to G-type 1 sample. These strains could not be 
typed through PCR. All samples that were P-typed through 
sequencing were P[8]. The only sample G-typed through 
sequencing was G9.
RV-A strains were detected in 133 (29%) of 464 sam-
ples. Genotype distribution showed a different proﬁ  le for 
each year: 45% G9P[8], 30% G3P[8], 14% G1P[8], and 
1.4% G2P[4] in 2005; 41% G2P[4], 18% G3P[8], and 15% 
G9P[8] in 2006; and 96% G2P[4] in 2007 (Table).
In the 18 months from July 2006 through December 
2007, almost all RV-A–positive samples (35/36, 97%) 
showed G2P[4] speciﬁ  city, which suggests a shift in geno-
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detection since 2006. When the pre- and postvaccination 
periods were compared, these changes in genotype distri-
bution were found to be accompanied by a signiﬁ  cant re-
duction in the detection rate of RV-A from 38% (73/193) in 
2005 to 24% (26/109) in 2007 (p = 0.012 by χ2 test).  Vac-
cination rates in the RV-A–positive and –negative groups 
(considering only children eligible for full vaccination) 
were 29% (4/14) and 58% (35/60), respectively (odds ra-
tio 0.29; 95% conﬁ  dence interval 0.07–1.15; p = 0.043 by 
Fisher exact test, 1-sided. The 4 RV-A–positive vaccinated 
children were infected with G2P[4] genotype.
Conclusions
The ﬁ  rst studies that assessed the RV-A genotype dis-
tribution after the introduction of Rotarix were carried out in 
northeastern Brazil (3–5). They offered the hypothesis that 
vaccination with the monovalent G1P[8] vaccine possibly 
created conditions in which RV-A G2P[4] could acquire 
selective advantage over P[8] genotypes (5). Nevertheless, 
a temporal periodicity, within the ≈10-year cyclic pattern 
of G2P[4] occurrence in Brazil, should be considered to 
explain the increased detection of this genotype since 2006. 
This periodicity could coincide with RV-A vaccine intro-
duction and the consequent reduction of circulation of non-
G2 strains.  
G2P[4] RV-A was not detected from 2000 to 2004 
in Rio de Janeiro (2–6); it was identiﬁ  ed in 2005 (1.4%) 
and reemerged in 2006 (41%). Similarly, in northern Bra-
zil, RV-A G2P[4] was detected in 2005 after a period of 
absence (A. Linhares, pers. comm.). When other Latin 
American countries are considered, an outbreak of RV-A 
gastroenteritis with a high rate of G2P[4] detection was re-
cently described in Honduras (12). According to Patel et 
al. (13), ongoing surveillance in El Salvador, Guatemala, 
and Honduras showed that G2P[4] was the predominant 
circulating strain in 2006 (68%–81%). In Argentina, this 
genotype was also circulating in 2006 (J. Stupka, pers. 
comm.). RV-A with short electropherotype, characterized 
as G2P[4], was detected at high frequency in 2005 in Para-
guay, after a 6-year absence (14). In these South American 
countries that border Brazil, there are no RV-A immuniza-
tion campaigns, and G2P[4] was detected before introduc-
tion of Rotarix in Brazil. 
In Bangladesh, the rate of G2P[4] detection increased 
recently (43% in 2005–2006) (15). The detection of G2P[4] 
since 2005 in countries where RV-A vaccination is not im-
plemented reinforces the possibility of natural reemergence 
of this genotype. 
Our data also suggest a signiﬁ  cant reduction in the rate 
of RV-A detection between the pre- and postvaccination 
periods. The comparison of vaccination rates between RV-
A–positive and –negative children, even with a small sam-
ple size, suggests that vaccinated children have a reduced 
risk for severe RV-A diarrhea. 
This survey is among the ﬁ  rst to evaluate the effects 
of Rotarix in Brazil, the ﬁ  rst Latin American country to 
introduce universal rotavirus vaccination. We believe that 
the emergence of strains that may escape protection can be 
a challenge to the RV-A immunization program in Brazil 
and needs to be continuously monitored. 
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Table. Frequency of rotavirus A infection and distribution of G and P genotypes from February 2005 through December 2007, Rio de
Janeiro, Brazil* 
Vaccination status 
and year  No. samples 
No. (%) rotavirus 
positive
No. (%) 
G1P[8]  
No. (%) 
G2P[4]  
No. (%) 
G3P[8] 
No. (%) 
G9P[8] 
No. (%) other genotypes, 
mixed or not typeable 
Ineligible for full 
vaccination†
  2005  193 73 (38)  10 (14)  1 (1.4)  22 (30)  33 (45)  7 (9.5) 
  2006  148 34 (23)  1 (2.9)  14 (41)  6 (8)  5 (5)  8 (23) 
  2007  49 12 (24)  1 (8)  11 (92)  – – –
Vaccinated‡
 2006  6 Negative§
  2007  33 4 (12)  – 4 (100)  – – –
Not vaccinated 
 2006  8 Negative§
  2007  27 10 (37)  – 10 (100)  – – –
Total 464 133 (29)  12 (9)  40 (30)  28 (21)  38 (29)  15 (11) 
*–, absence of genotypes. 
†Born before January 1, 2006, or <4 months of age. 
‡Children were considered vaccinated if they had received 2 doses of vaccine.  
§All stool samples were negative for rotavirus.  Rotavirus Genotypes and Vaccine, Brazil
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